4Tech Secures $29M in Series B Financing

4tech_logo4Tech Inc., a developer of solutions for transcatheter treatment of Tricuspid Regurgitation (TR), secured $29m in series B financing.

The round was led by Valiance and RMM, with participation from existing and new investors NeoMed Management, and a group of business angels within the Aortic and Mitral Structural Heart Disease.

The funds will be used to gain European market entry for the 4Tech TriCinchâ„¢ system for TTVR.

Led by Carine Schorochoff, Co-Founder and CEO, 4Tech has developed the TriCinchâ„¢ system, a ranscatheter device designed to allow clinicians to repair a diseased tricuspid heart valve in a reproducible interventional procedure.

The company is incorporated in Delaware, USA, with operations in Galway, Ireland as 4Tech Cardio Ltd.



Join the discussion